Anna Schuh, MD, PhD, MRCP, FRCPath, from the University of Oxford, Oxford, UK, is an Associate Professor and Director of Molecular Diagnostics in the Department of Oncology, as well as an Honorary Consultant Hematologist at Oxford University Hospitals. She specializes in chronic lymphocytic leukemia (CLL).
Prof. Schuh started her medical training in Germany, obtaining her medical degree from Cologne University. She subsequently moved to Oxford where she completed academic and clinical hematology training. As well as her roles at the University of Oxford, Prof. Schuh is the clinical lead for CLL for the Thames Valley, lead of the Genomics England Clinical Interpretation Partnership for Haematological Malignancies, and NCRI-appointed Chair of chronic lymphocytic leukemia research in the UK. She also chaired the UK CLL forum from 2016-2019 and is a current board member of the iwCLL. An esteemed CLL researcher, Prof. Schuh has been the Principal or Chief Investigator on over 50 clinical trials and has authored/co-authored more than 260 peer-reviewed publications.
Speaking on molecular diagnostic technologies in CLL
As globally renowned authority in CLL, Prof. Schuh’s career-spanning interest in the development and implementation of novel diagnostic technologies has changed clinical practice worldwide. Her work focuses on identifying disease markers for early cancer detection, risk grouping and optimal therapy selection. She has a particular interest in genomics and was heavily involved in the 100,000 genomes project. Her lab was the first group to publish a longitudinal whole genome sequencing study for CLL patients receiving treatment and established the first fully certified next generation sequencing panels for cancer diagnosis within the NHS.
Prof. Schuh’s recent research is centered on improving early diagnosis in B-cell malignancies with biomarkers, as well as developing a liquid biopsy test for endemic EBV-driven pediatric lymphoma. Furthermore, Prof. Schuh has a research interest in the rare Richter’s Syndrome and is the Chief Investigator of the first Phase II clinical trial in this patient group.